How Much Does Belsomra (Suvorexant) Cost in Arkansas in 2026?

Arkansas Retail Pricing for Belsomra in 2026

The gap between Belsomra's list price and what Arkansas residents actually pay is significant. Merck sets the wholesale acquisition cost (WAC) at $340 for a 30-tablet supply, but competitive pharmacy pricing, discount cards, and insurer negotiations bring the real out-of-pocket figure much lower for most patients.

Cash-Pay Prices Across Arkansas Pharmacies

Across chain and independent pharmacies in Arkansas, the average cash-pay price in 2026 sits near $85 per month. That figure reflects negotiated rates through pharmacy benefit managers and discount aggregator platforms. Prices vary by location: a Walgreens in Little Rock may quote differently than an independent pharmacy in Fayetteville.

Patients paying out of pocket should request a price comparison before filling. Arkansas law allows pharmacists to inform patients when a lower-cost option exists, including manufacturer coupons. A 30-day supply of Belsomra 10 mg and Belsomra 20 mg are typically priced identically, so dose escalation does not increase monthly costs.

Why the List Price Rarely Applies

The $340 WAC represents what wholesalers pay Merck before any rebates. Almost no patient pays this amount. Commercial insurers negotiate rebates that reduce their net cost by 40% to 70%, and those savings flow partially to patients through lower copays. Cash-pay discount programs from GoodRx, RxSaver, and SingleCare typically bring the price into the $75 to $110 range at Arkansas pharmacies. Patients without insurance should compare at least three pharmacies and one discount aggregator before filling a Belsomra prescription.

Arkansas Medicaid Coverage for Belsomra

Arkansas Medicaid does include Belsomra on its preferred drug list, but access requires prior authorization (PA). The PA process exists because Medicaid formulary committees classify dual orexin receptor antagonists as second-line agents for insomnia, behind generic options like zolpidem, trazodone, and doxepin.

Prior Authorization Requirements

To obtain PA approval, prescribers must typically document that the patient has tried and failed (or has a contraindication to) at least one first-line generic sleep medication. The Arkansas Department of Human Services Pharmacy Program reviews these requests. Standard turnaround time is 24 to 72 hours for non-urgent requests. Emergency supplies of up to 72 hours may be dispensed while the PA is pending.

What Triggers a Denial

Common reasons for PA denial include incomplete documentation, failure to demonstrate a trial of generic alternatives, and prescribing above the FDA-approved maximum dose of 20 mg. Prescribers should include specific dates and durations of prior medication trials, along with documented reasons for discontinuation (lack of efficacy, adverse effects, or both). Arkansas Medicaid allows one appeal per denial, and the appeal must include new clinical information not submitted in the original request.

The Herring et al. Trial published in The Lancet Neurology (N=250 per arm in the primary efficacy population) demonstrated that suvorexant significantly improved subjective total sleep time by 22 minutes versus placebo over 3 months, with sustained benefit at 12 months 1. Citing this data in a PA letter can support the clinical rationale when generic alternatives have failed.

Insurance Coverage Beyond Medicaid

Most major commercial insurers operating in Arkansas place Belsomra on a Tier 3 (preferred brand) or Tier 4 (non-preferred brand) formulary position. Coverage details vary by plan, but the pattern is consistent: step therapy through a generic hypnotic is required before Belsomra is approved.

Blue Cross Blue Shield of Arkansas

BCBS Arkansas generally covers Belsomra on Tier 3 with step therapy. Patients must have documented failure of or intolerance to at least one generic agent. Copays on Tier 3 brand medications typically range from $40 to $75 per month depending on the specific plan.

QualChoice and Arkansas Blue Cross

QualChoice, one of Arkansas's regional health plans, applies similar step-therapy criteria. Patients with a prior authorization on file can expect copays in the $35 to $65 range. Arkansas Blue Cross and other state-based plans follow parallel formulary logic. Patients should call the number on their pharmacy benefit card to confirm Belsomra's tier placement on their specific plan.

Medicare Part D

Medicare Part D plans in Arkansas generally cover Belsomra, though tier placement varies by plan. The Medicare Plan Finder tool at medicare.gov allows patients to search their specific plan. Most Part D plans place Belsomra on Tier 3 or Tier 4 with copays ranging from $42 to $95 per month after the deductible phase. The Merck savings card cannot be used alongside Medicare, Medicaid, or any federally funded program.

The Merck Belsomra Savings Card

Merck offers a manufacturer savings card for commercially insured patients that can reduce copays to as low as $0 to $30 per month, depending on the plan's negotiated rate. The card is available through the Merck website and through prescribers' offices.

Eligibility and Limitations

The savings card is available to patients with commercial (private) insurance. It is not available to patients enrolled in Medicare Part D, Medicaid, TRICARE, or any other federal or state government-funded healthcare program. The card typically covers up to $150 per prescription fill, and most commercially insured patients in Arkansas will pay between $0 and $30 out of pocket when combining their insurance benefit with the savings card.

Patients should confirm card activation before their first fill. Some Arkansas pharmacies require the pharmacist to manually enter the savings card BIN and PCN numbers. The card renews annually and has a maximum annual benefit cap (typically $1,800 per calendar year, though Merck adjusts this periodically).

Compounded Suvorexant in Arkansas

Compounded suvorexant is available in Arkansas through licensed 503A compounding pharmacies. Under federal law (Drug Quality and Security Act, Section 503A), a compounding pharmacy can prepare patient-specific prescriptions for suvorexant when a valid prescription exists and the compounded product is not essentially a copy of a commercially available drug 2.

Legal Status in Arkansas

Arkansas follows federal 503A compounding regulations. The Arkansas State Board of Pharmacy licenses and inspects compounding pharmacies within the state. A prescriber must write a patient-specific prescription, and the compounding pharmacy must use bulk pharmaceutical-grade suvorexant powder sourced from an FDA-registered supplier. The finished product must differ from the commercially available Belsomra tablet in a clinically meaningful way (different dose, different dosage form, or a formulation for a patient who cannot tolerate an inactive ingredient in the commercial product).

Cost of Compounded Suvorexant

Compounded suvorexant pricing varies widely. Some 503A pharmacies in Arkansas offer compounded capsules for $30 to $60 per month, depending on the dose and quantity. Patients should verify that the compounding pharmacy is licensed by the Arkansas State Board of Pharmacy and that the facility has a clean inspection history. Compounded medications are not covered by most insurance plans, so the entire cost is typically out of pocket.

When Compounding Makes Clinical Sense

Compounded suvorexant is most appropriate for patients who need a dose not commercially available (Belsomra comes only in 5 mg, 10 mg, 15 mg, and 20 mg tablets), who have an allergy to an inactive ingredient in the branded product, or who require a different dosage form such as a liquid or sublingual preparation. The FDA's compounding guidance emphasizes that compounding should address an individual patient's medical need rather than serve as a cost-reduction strategy for an available commercial product.

Telehealth Prescribing of Belsomra in Arkansas

Arkansas permits telehealth prescribing of Belsomra. The Arkansas State Medical Board allows physicians to prescribe Schedule IV controlled substances (suvorexant is Schedule IV) via telemedicine after establishing a valid patient-physician relationship through an audio-video encounter 3.

How Telehealth Visits Work for Belsomra

A patient in Arkansas can schedule a video consultation with a licensed prescriber, discuss their insomnia history, and receive a Belsomra prescription sent electronically to their preferred Arkansas pharmacy. The prescriber must hold an active Arkansas medical license or be practicing under the Interstate Medical Licensure Compact.

Most telehealth platforms charge $50 to $150 for an initial insomnia consultation. Follow-up visits are typically $30 to $75. Some platforms include the consultation fee in a subscription that also covers the medication cost. Patients should confirm that the platform's prescribers are comfortable with Schedule IV medications, as some telehealth services restrict controlled substance prescribing.

Suvorexant Pricing Compared to Alternatives

Understanding how Belsomra's cost compares to other insomnia medications helps Arkansas patients and prescribers make informed decisions.

Generic Sleep Medications

Zolpidem (generic Ambien) costs $5 to $15 per month at most Arkansas pharmacies. Trazodone at low doses (25 to 100 mg) runs $4 to $10 per month. Doxepin 3 mg or 6 mg (generic Silenor) costs $15 to $40 per month. These agents remain the most affordable insomnia treatments, which is why insurers and Medicaid require a trial of generics before covering Belsomra.

Other Dual Orexin Receptor Antagonists

Lemborexant (Dayvigo), another DORA approved by the FDA, carries a list price comparable to Belsomra at approximately $350 to $380 per month. Average cash-pay pricing in Arkansas is similar, in the $80 to $100 range. Lemborexant and suvorexant have not been compared head-to-head in a randomized trial, but both showed statistically significant improvements in sleep onset and maintenance in their respective Phase 3 programs. The Herring et al. Trial showed suvorexant improved wake after sleep onset (WASO) by approximately 25 minutes versus placebo at Month 1 1.

Cost-Effectiveness Considerations

A 2019 analysis published in the Journal of Managed Care & Specialty Pharmacy found that DORAs as a class were cost-effective compared to benzodiazepine receptor agonists when accounting for reduced fall risk and next-day cognitive impairment in older adults 4. For patients over age 65, where the American Geriatrics Society Beers Criteria recommend against benzodiazepines and Z-drugs, suvorexant may be the more appropriate first-line option regardless of cost differential.

Strategies to Lower Your Belsomra Cost in Arkansas

Several approaches can reduce out-of-pocket spending on Belsomra for Arkansas residents.

Step 1: Check Your Insurance Formulary

Call the number on your pharmacy benefit card and ask specifically about Belsomra's tier and any step-therapy requirements. If your plan covers it, confirm your expected copay.

Step 2: Apply the Merck Savings Card

If you have commercial insurance, activate the Merck Belsomra Savings Card before your first fill. This alone can reduce copays to $0 to $30 per month.

Step 3: Compare Pharmacy Prices

Use GoodRx, RxSaver, or SingleCare to compare Belsomra prices at Arkansas pharmacies near you. Prices can differ by $30 or more between pharmacies in the same city.

Step 4: Ask About 90-Day Fills

Many Arkansas pharmacies and mail-order services offer a per-unit discount on 90-day fills. A 90-day supply may cost less per tablet than three separate 30-day fills.

Step 5: Explore Patient Assistance

Merck's patient assistance program (Merck Helps) provides Belsomra at no cost to qualifying uninsured or underinsured patients with household income at or below 400% of the federal poverty level. Applications are available through the Merck website or by calling 800-727-5400.

Dr. Michael Sateia, former chief of sleep medicine at Dartmouth-Hitchcock Medical Center and lead author of the American Academy of Sleep Medicine's 2017 clinical practice guidelines, stated: "Suvorexant represents a mechanistically distinct approach to insomnia treatment that targets the wake-promoting orexin system rather than broadly suppressing CNS activity" 5.

The AASM clinical practice guideline, published in the Journal of Clinical Sleep Medicine (2017), recommends suvorexant for sleep maintenance insomnia in adults, grading the evidence as "weak" based on a balance of benefits and side effects across available trials 5.

Safety and Scheduling Considerations

Suvorexant is classified as a Schedule IV controlled substance by the DEA, reflecting a low but real potential for dependence. The FDA-approved prescribing information lists somnolence (7% vs. 3% placebo), headache, and dizziness as the most common adverse effects at the 20 mg dose 6. Complex sleep behaviors (sleepwalking, sleep-driving) have been reported in post-marketing surveillance, prompting an FDA boxed warning added in 2019 that applies to all orexin receptor antagonists.

In the Herring et al. Key trial, suvorexant at 40 mg (higher than the currently approved maximum of 20 mg) and 20 mg doses both demonstrated significant improvements in polysomnographic total sleep time versus placebo at Month 1 (P<0.001), with the 20 mg dose showing a 16.4-minute improvement in latency to persistent sleep 1. The FDA ultimately approved the 5 mg, 10 mg, 15 mg, and 20 mg doses, rejecting the 30 mg and 40 mg doses over next-morning impairment concerns.

Arkansas patients filling a Belsomra prescription should expect the pharmacist to verify identity and may need to sign for the medication, consistent with Schedule IV dispensing requirements under Arkansas Code Annotated 17-92-101 et seq.

Patients aged 65 and older should start at 5 mg, per FDA labeling, and the prescriber should reassess after 7 to 14 days before dose escalation to 10 mg.